Adicet Bio, Inc. 8K

Adicet Bio reported Q2 2026 financial results, outlined key upcoming clinical and regulatory milestones for prula-cel and ADI-212, advanced its in vivo CAR-T platform, and announced the appointment of an Interim Chief Medical Officer.

Adicet Bio, Inc. filed a Form 8-K to furnish its second quarter 2026 financial results and provide business updates, highlighting upcoming clinical milestones for its lead programs and a key management change. The company plans a comprehensive Phase 1 clinical update in 3Q 2026 for prulacabtagene leucel (prula-cel) in lupus nephritis and systemic lupus erythematosus, informed by productive FDA interactions that are shaping a potential pivotal trial in LN expected to start in the second half of 2026, subject to regulatory clearance. Adicet also expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in 3Q 2026, with Phase 1 enrollment anticipated in 4Q 2026 pending approval, and is advancing an in vivo CAR-T platform with a broader update planned for the second half of 2026. Operationally, the company appointed board member Lloyd Klickstein, M.D., Ph.D. as Interim Chief Medical Officer following the departure of Dr. Julie Maltzman. For the quarter ended June 30, 2026, Adicet reported R&D expenses of $18.5 million, G&A expenses of $3.9 million, a net loss of $21.4 million (or $1.99 per share), and cash, cash equivalents, and short-term investments of $118.2 million, which it believes will fund operations into the second half of 2027.

Filing Facts

CIK

1720580

Ticker

-

Form

8K

Source Type

sec

Accession

0001720580-26-000049

Alert Tier

6